Articles On Kazia Therapeutics (ASX:KZA)

The company will present findings to date at the upcoming virtual American Society of Clinical Oncology annual meeting.

The proceeds will be applied directly to progressing and enriching the company’s research and development programs.

Participating in small cap raises is proving lucrative for investors, with shares in 47 small caps that tapped equity markets in April currently trading higher than the price at which they raised cash. Stockhead counted at least 66 offers i...

The proceeds will be applied directly to progressing and enriching the company’s research and development programs.

Kazia recently confirmed further positive data from its Phase I study of Cantrixil (TRX-E-001-2) in ovarian cancer.

Pre-revenue biotech and medtech companies are still not eligible for the Jobkeeper wage subsidy according to the ATO, a double whammy for a swathe of research-driven ASX businesses with large staff costs. The Jobkeeper program allows busine...

Proceeds from the SPP and recent placement will be used to progress the paxalisib clinical trial program and to complete analysis of the ongoing Phase I study of Cantrixil.

The company has received a large volume of acceptances in the last two days and wishes to ensure that shareholders have sufficient time to apply.

It’s still a relatively difficult market to raise capital in, particularly at the junior end, but there are some that have convinced investors to part with their hard earned cash. We run through just which small and micro caps successfully...

Clinical trials are being shuttered in increasing numbers in Australia because of the risks posed by COVID-19, but two companies this morning say theirs are moving ahead at speed. Prescient Therapeutics (ASX:PTX) says its phase 1b study of...

The COVID-19 pandemic has led to 527 clinical trials being shut down in Australia and New Zealand the last two months, up 36 per cent on the prior two months as many organisations deem the patient risk of exposure to be too high. Globally,...

Patients recruited to the study all had advanced metastatic ovarian cancer and had failed or become resistant to six prior therapies before commencing Cantrixil treatment.

Phase II study data recently provided evidence that paxalisib may achieve meaningful extension of patient life.

The company will also launch a Share Purchase Plan to allow eligible existing holders to acquire new shares at the same price as the shares issued under the placement.

The oncology-focused biotechnology company has two clinical-stage drug development candidates in the pipeline.

In proof that biotechs will deliver market returns even during a pandemic, two companies this morning have issued clinical trial results and watched their share prices rocket. Pot stock Zelira Therapeutics (ASX:ZLD) has received the full re...

Kazia recently completed recruitment for the phase II clinical trial testing its development drug paxalisib on aggressive brain cancer.

The Australian oncology-focused biotechnology company has two clinical-stage drug development candidates - paxalisib (GDC-0084) and TRX-E-002-1 (Cantrixil).

Kazia is an oncology-focused biotechnology company developing the drug paxalisib to treat brain cancer.

Neuren Pharmaceuticals (ASX: NEU) is getting interesting results from a mouse trial of a treatment for Phelan-McDermid syndrome (PMS), a rare genetic illness which exhibits symptoms of conditions including autism and epilepsy. The study fou...

Peter Switzer speaks to Kazia Therepeutics (KZA) CEO James Garner about the company's work to develop a new drug for cancer.

Kazia had a transformational year in 2019 with initial clinical efficacy read-outs from both its key R&D programs.

Kazia has concrete signals of clinical efficacy for its GDC-0084 program paxalisib in the exact patient population that is targeted for commercialisation.

Kazia plans to participate in the GBM AGILE international study as its primary path-to-market strategy for GDC-0084.

You may have heard the saying “it’s not brain surgery” in the context of trying to prove something easy. Well there is a reason  — our brains are among the most difficult parts of our body to treat. There are a few ASX small caps trying to...

The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small...

The company anticipates further data read-outs in calendar 2020, along with the transition of GDC-0084 into a pivotal study for FDA registration.

Kazia plans to participate in the GBM AGILE international multi-drug adaptive phase II / III study as its primary path-to-market strategy for GDC-0084.

Kazia Therapeutics’ (ASX: KZA) lead drug GDC-0084 has been selected for use in GBM AGILE, which is an international academic-led glioblastoma study. According to Kazia, GBM AGILE is an adaptive phase II/phase III study that will test multip...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Australian oncology company Kazia Therapeutics (ASX:KZA) has released interim data from its ongoing phase 2 study of GDC-0084 in glioblastoma, the most common and most aggressive form of primary brain cancer.

Majority of patients in the first stage of the study remain alive more than a year after diagnosis of glioblastoma, an aggressive form of primary brain cancer.

Biotechnology company Kazia Therapeutics (ASX: KZA) has reported early data from a phase 2 study into the effects of lead candidate GDC-0084 on newly-diagnosed brain glioblastomas in adults has shown the drug may delay the cancer’s progress...

The company has capitalised on recent share price appreciation driven by emerging data from broad-based clinical trial programs and has strengthened its balance sheet while minimising investor dilution.

Got 90 seconds? Then listen to Kazia Therapeutics CEO and Executive Director Dr. James Garner tell us about his AusBiotech Invest presentation and the company’s recent capital raising. Kazia Therapeutics (ASX:KZA) is an oncology focused dru...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

Dual Listing: When a stock gets listed on two or more stock exchanges, we say that the stock has a dual listing. Why companies go for dual listing? The biggest advantage of dual listing is that the companies get to address a large group of...

The company has capitalised on recent share price appreciation driven by emerging data from broad-based clinical trial programs and has strengthened its balance sheet while minimising investor dilution.

The cancer therapeutics developer expects its shares will swap hands again by Monday.

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the stethoscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim interviews Dr James Garner, CEO & Executive...

Kazia has presented at the annual Congress of the European Society for Medical Oncology (ESMO), held in Barcelona.

Results from phase II study of its brain cancer therapeutic GDC-0084 are expected next quarter.

The company is in discussion with clinicians and potential collaborators regarding the strategy for further development of GDC-0084 in glioblastoma.

Sydney-based oncology biotechnology company Kazia Therapeutics, formerly known as Novogen, has been recognised at the 2019 ANZLF Trans-Tasman Innovation and Growth Awards.

The awards are run by the Australian New Zealand Leadership Forum which brings senior businesses and government leaders together to help both nations prosper in the global economy.

Toxicity can be a significant challenge in the treatment of childhood cancer, so it is very encouraging that GDC-0084 appears to have an acceptable tolerability profile.

The report points out Kazia’s accelerated 2023 GDC-0084 approval and maintains its base case 2024 launch scenario with an updated valuation.